DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Semuloparin sodium is an investigational drug.
There have been 9 clinical trials for Semuloparin sodium. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2008.
The most common disease conditions in clinical trials are Venous Thromboembolism, Thromboembolism, and Hip Fractures. The leading clinical trial sponsors are Sanofi and [disabled in preview].
Recent Clinical Trials for Semuloparin sodium
|Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line||Sanofi||Phase 2|
|Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility||Sanofi||Phase 3|
|Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery||Sanofi||Phase 3|